(Q37024419)

17 August 2017

1 reference

title

Thiazolidinediones and diabetic nephropathy: need for a closer examination? (English)

1 reference

17 August 2017

1 reference

Pantelis A Sarafidis

1

1 reference

17 August 2017

publication date

1 January 2007

1 reference

Journal of the cardiometabolic syndrome

17 August 2017

published in

1 reference

17 August 2017

volume

2

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

297-301

1 reference

Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000).

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Goodpasture syndrome during the course of a Schönlein-Henoch purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Cardiometabolic syndrome and chronic kidney disease: what is the link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Antihypertensive agents, insulin sensitivity, and new-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

The importance of blood pressure control in the patient with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Renal actions of endothelin: linking cellular signaling pathways to kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Paradoxes of nitric oxide in the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Insulin resistance and its treatment by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4564.2007.07834.X

10.1111/J.1559-4564.2007.07834.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference